Skip to main content
4BASEBIO PLC logo

4BASEBIO PLC — Investor Relations & Filings

Ticker · 4BB ISIN · GB00BMCLYF79 LEI · 213800E2DX9EAIUNCB30 IL Manufacturing
Open in API
Filings indexed 92 across all filing types
Latest filing 2024-04-10 Regulatory Filings
Country GB United Kingdom
Listing IL 4BB

About 4BASEBIO PLC

https://www.4basebio.com/

4BASEBIO PLC is a biotechnology company specializing in the design and manufacturing of synthetic DNA for next-generation therapeutics and vaccines. The company provides high-purity, Good Manufacturing Practice (GMP) grade nucleic acid products, including its proprietary opDNA®, as a plasmid-free alternative to traditional methods. Its technology is engineered to accelerate development timelines, enhance safety, and improve manufacturing scalability for applications in genetic medicine, including mRNA vaccines, viral vector-based gene therapies, and gene editing. 4basebio's solutions aim to eliminate production bottlenecks and de-risk manufacturing for partners in the pharmaceutical and biotechnology sectors.

Recent filings

Filing Released Lang Actions
4basebio Plc - 4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
Regulatory Filings Classification · 1% confidence The document is a press release announcing a significant business development: the supply of DNA products to a Tier 1 Pharma client for a vaccine program. It contains market-sensitive information ('inside information for the purposes of Article 7 of EU Regulation 596/2014') and is distributed via PR Newswire. This type of announcement, detailing operational progress, contracts, or material updates that are not standard periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since there is no specific category for 'Business Update Press Release' and it is not a formal financial filing, the most appropriate fallback category is 'Regulatory Filings' (RNS), which covers general regulatory announcements not covered elsewhere. The document length is short (3396 chars), but it is the primary content, not an announcement *about* another report.
2024-04-10 English
4basebio Plc - 4basebio client's Phase I clinical trials for opDNA™ based mRNA vaccine
Legal Proceedings Report Classification · 1% confidence The document is a press release issued via PR Newswire announcing a key milestone: a client progressing into Phase I clinical trials using the company's manufactured product (opDNA™). This type of announcement, detailing operational progress, partnerships, or specific scientific achievements outside of standard periodic financial reporting (like 10-K or IR), typically falls under general regulatory announcements or news releases. Since it is not a formal financial report (10-K, IR, ER, MRQ), a management change (MANG), a director trade (DIRS), or a specific financing event (CAP), the most appropriate classification is the general regulatory/news category, RNS, as it is a formal announcement to the market about a significant operational development. The document length is short (3947 chars), but it contains the full substance of the news, not just a pointer to an attached report, so RPA is less likely than RNS for this type of substantive operational update.
2024-03-21 English
4basebio Plc - 4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of Excellence
Regulatory Filings Classification · 1% confidence The document is a press release announcing that 4basebio PLC has been awarded a tender to supply synthetic DNA to CPI's RNA Centre of Excellence. It contains standard press release formatting, contact information, and boilerplate 'About' sections. This type of announcement, which details a business development or contract win, is typically classified as a general regulatory announcement or news release, as it does not fit the specific criteria for financial reports (10-K, IR, ER), management changes (MANG), or shareholder actions (DIV, DVA). Since it is a formal announcement distributed via PR Newswire, and it doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP), the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for miscellaneous regulatory news.
2024-03-01 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' concerning an acquisition or disposal of voting rights in 4BASEBIO PLC. This form is used to report changes in significant share ownership that cross specific notification thresholds. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers 'Notification of changes in significant share ownership levels (crossing thresholds)'. The document is not an earnings release, annual report, or a general regulatory announcement (RNS), but a specific filing about insider/major shareholder activity.
2024-02-06 English
4basebio Plc - Exercise of Options
Share Issue/Capital Change Classification · 1% confidence The document announces the exercise of employee stock options (EMI options) by an employee, resulting in the issuance of 9,000 new ordinary shares. It explicitly mentions the application for these shares to be admitted to trading on AIM and updates the total number of voting rights (Total Voting Rights). This type of announcement, dealing with changes in share capital due to option exercises and subsequent admission to trading, falls under the category of share capital changes or insider transactions. Since it involves the issuance of new shares and a change in the total share count, it aligns closely with 'Share Issue/Capital Change' (SHA). It is not a Director's Dealing (DIRS) as it relates to employee options, not a director's personal transaction disclosure, nor is it a general financing update (CAP). Given the direct impact on the number of shares in issue, SHA is the most appropriate classification.
2024-02-06 English
4basebio Plc - Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is a 'TR-1: Standard form for notification of major holdings' concerning an acquisition of voting rights in 4BASEBIO PLC. This form is used to report changes in significant share ownership, specifically when a shareholder crosses or reaches a notification threshold. This directly corresponds to the definition of Major Shareholding Notification (MRQ). The document details the shareholder, the date the threshold was crossed (30-Jan-2024), and the resulting total positions (52.587160%).
2024-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.